Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study

Lisa Bodei, Marta Cremonesi, Stefania Zoboli, Chiara Grana, Mirco Bartolomei, Paola Rocca, Maurizio Caracciolo, Helmut R. Mäcke, Marco Chinol, Giovanni Paganelli

Research output: Contribution to journalArticle

251 Citations (Scopus)

Abstract

The aim of this study was to determine the maximum tolerated dose of 90Y-DOTATOC per cycle administered in association with amino acid solution as kidney protection in patients with somatostatin receptor-positive tumours. Forty patients in eight groups received two cycles of 90Y-DOTATOC, with activity increased by 0.37 GBq per group, starting at 2.96 and terminating at 5.55 GBq. All patients received lysine ± arginine infusion immediately before and after therapy. Forty-eight percent developed acute grade I-II gastrointestinal toxicity (nausea and vomiting) after amino acid infusion whereas no acute adverse reactions occurred after 90Y-DOTATOC injection up to 5.55 GBq/cycle. Grade III haematological toxicity occurred in three of seven (43%) patients receiving 5.18 GBq, which was defined as the maximum tolerable activity per cycle. Objective therapeutic responses occurred. Five GBq per cycle is the recommended dosage of 90Y-DOTATOC when amino acids are given to protect the kidneys. Although no patients developed acute kidney toxicity, delayed kidney toxicity remains a major concern, limiting the cumulative dose to ∼25 Gy. The way forward with this treatment would seem to be to identify more effective renal protective agents, in order to be able to increase the cumulative injectable activity and hence tumour dose.

Original languageEnglish
Pages (from-to)207-216
Number of pages10
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume30
Issue number2
Publication statusPublished - Feb 1 2003

Fingerprint

Radioisotopes
Amino Acids
Kidney
Renal Agents
Activity Cycles
Therapeutics
Protective Agents
Somatostatin Receptors
Injections
Maximum Tolerated Dose
Nausea
Lysine
Vomiting
Arginine
Neoplasms
DOTA-Tyr(3)-90Y-octreotide

Keywords

  • Y-DOTATOC
  • Peptides
  • Receptor radiotherapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion : A phase I study. / Bodei, Lisa; Cremonesi, Marta; Zoboli, Stefania; Grana, Chiara; Bartolomei, Mirco; Rocca, Paola; Caracciolo, Maurizio; Mäcke, Helmut R.; Chinol, Marco; Paganelli, Giovanni.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 30, No. 2, 01.02.2003, p. 207-216.

Research output: Contribution to journalArticle

@article{3e4b94e8c94b4ff7b61b494a20b82cf1,
title = "Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study",
abstract = "The aim of this study was to determine the maximum tolerated dose of 90Y-DOTATOC per cycle administered in association with amino acid solution as kidney protection in patients with somatostatin receptor-positive tumours. Forty patients in eight groups received two cycles of 90Y-DOTATOC, with activity increased by 0.37 GBq per group, starting at 2.96 and terminating at 5.55 GBq. All patients received lysine ± arginine infusion immediately before and after therapy. Forty-eight percent developed acute grade I-II gastrointestinal toxicity (nausea and vomiting) after amino acid infusion whereas no acute adverse reactions occurred after 90Y-DOTATOC injection up to 5.55 GBq/cycle. Grade III haematological toxicity occurred in three of seven (43{\%}) patients receiving 5.18 GBq, which was defined as the maximum tolerable activity per cycle. Objective therapeutic responses occurred. Five GBq per cycle is the recommended dosage of 90Y-DOTATOC when amino acids are given to protect the kidneys. Although no patients developed acute kidney toxicity, delayed kidney toxicity remains a major concern, limiting the cumulative dose to ∼25 Gy. The way forward with this treatment would seem to be to identify more effective renal protective agents, in order to be able to increase the cumulative injectable activity and hence tumour dose.",
keywords = "Y-DOTATOC, Peptides, Receptor radiotherapy",
author = "Lisa Bodei and Marta Cremonesi and Stefania Zoboli and Chiara Grana and Mirco Bartolomei and Paola Rocca and Maurizio Caracciolo and M{\"a}cke, {Helmut R.} and Marco Chinol and Giovanni Paganelli",
year = "2003",
month = "2",
day = "1",
language = "English",
volume = "30",
pages = "207--216",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "2",

}

TY - JOUR

T1 - Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion

T2 - A phase I study

AU - Bodei, Lisa

AU - Cremonesi, Marta

AU - Zoboli, Stefania

AU - Grana, Chiara

AU - Bartolomei, Mirco

AU - Rocca, Paola

AU - Caracciolo, Maurizio

AU - Mäcke, Helmut R.

AU - Chinol, Marco

AU - Paganelli, Giovanni

PY - 2003/2/1

Y1 - 2003/2/1

N2 - The aim of this study was to determine the maximum tolerated dose of 90Y-DOTATOC per cycle administered in association with amino acid solution as kidney protection in patients with somatostatin receptor-positive tumours. Forty patients in eight groups received two cycles of 90Y-DOTATOC, with activity increased by 0.37 GBq per group, starting at 2.96 and terminating at 5.55 GBq. All patients received lysine ± arginine infusion immediately before and after therapy. Forty-eight percent developed acute grade I-II gastrointestinal toxicity (nausea and vomiting) after amino acid infusion whereas no acute adverse reactions occurred after 90Y-DOTATOC injection up to 5.55 GBq/cycle. Grade III haematological toxicity occurred in three of seven (43%) patients receiving 5.18 GBq, which was defined as the maximum tolerable activity per cycle. Objective therapeutic responses occurred. Five GBq per cycle is the recommended dosage of 90Y-DOTATOC when amino acids are given to protect the kidneys. Although no patients developed acute kidney toxicity, delayed kidney toxicity remains a major concern, limiting the cumulative dose to ∼25 Gy. The way forward with this treatment would seem to be to identify more effective renal protective agents, in order to be able to increase the cumulative injectable activity and hence tumour dose.

AB - The aim of this study was to determine the maximum tolerated dose of 90Y-DOTATOC per cycle administered in association with amino acid solution as kidney protection in patients with somatostatin receptor-positive tumours. Forty patients in eight groups received two cycles of 90Y-DOTATOC, with activity increased by 0.37 GBq per group, starting at 2.96 and terminating at 5.55 GBq. All patients received lysine ± arginine infusion immediately before and after therapy. Forty-eight percent developed acute grade I-II gastrointestinal toxicity (nausea and vomiting) after amino acid infusion whereas no acute adverse reactions occurred after 90Y-DOTATOC injection up to 5.55 GBq/cycle. Grade III haematological toxicity occurred in three of seven (43%) patients receiving 5.18 GBq, which was defined as the maximum tolerable activity per cycle. Objective therapeutic responses occurred. Five GBq per cycle is the recommended dosage of 90Y-DOTATOC when amino acids are given to protect the kidneys. Although no patients developed acute kidney toxicity, delayed kidney toxicity remains a major concern, limiting the cumulative dose to ∼25 Gy. The way forward with this treatment would seem to be to identify more effective renal protective agents, in order to be able to increase the cumulative injectable activity and hence tumour dose.

KW - Y-DOTATOC

KW - Peptides

KW - Receptor radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=10744230217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744230217&partnerID=8YFLogxK

M3 - Article

C2 - 12552338

AN - SCOPUS:10744230217

VL - 30

SP - 207

EP - 216

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 2

ER -